ArticleCancers2020

Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients.

Camille Moreau-Bachelard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.